Gardiquimod

Last updated
Gardiquimod
Gardiquimod.svg
Identifiers
  • 1-(4-Amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.233.311 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H23N5O
Molar mass 313.405 g·mol−1
3D model (JSmol)
  • CCNCc1nc2c(n1CC(C)(C)O)c3ccccc3nc2N
  • InChI=1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20)
  • Key:FHJATBIERQTCTN-UHFFFAOYSA-N
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Gardiquimod is an experimental drug which acts selectively at both mouse and human forms of toll-like receptor 7 (TLR7). It functions as an immune response modifier. [1] [2] The core structure is 1H-imidazo[4,5-c]quinoline, as found in related drugs such as imiquimod and resiquimod. It is structurally very similar to resiquimod differing only by an oxygen for nitrogen switch.

References

  1. ↑ Ma F, Zhang J, Zhang J, Zhang C (September 2010). "The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice". Cellular & Molecular Immunology. 7 (5): 381–8. doi:10.1038/cmi.2010.30. PMC   4002679 . PMID   20543857.
  2. ↑ Buitendijk M, Eszterhas SK, Howell AL (June 2013). "Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells". AIDS Research and Human Retroviruses. 29 (6): 907–18. doi:10.1089/aid.2012.0313. PMC   3653394 . PMID   23316755.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.